Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes

Aims/hypothesis The Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial reported that 3 years of therapy with rosiglitazone reduced the primary outcome of diabetes or death by 60%. Here we investigated whether an effect on diabetes prevention persists more than 1.5...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetologia 2011-03, Vol.54 (3), p.487-495
Hauptverfasser:	Gerstein, H C, Mohan, V, Avezum, A, Bergenstal, R M, Chiasson, J-L, Garrido, M, MacKinnon, I, Rao, P V, Zinman, B, Jung, H, Joldersma, L, Bosch, J, Yusuf, S
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological and medical sciences Diabetes Diabetes Mellitus - drug therapy Diabetes Mellitus - prevention & control Diabetes. Impaired glucose tolerance Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fasting Female Glucose Health sciences Human Physiology Humans Hypoglycemic Agents - therapeutic use Internal Medicine Male Medical research Medical sciences Medicine Medicine & Public Health Metabolic Diseases Middle Aged Plasma Prevention Ramipril - therapeutic use Research centers Thiazolidinediones - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!